Literature DB >> 20889599

Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases -- a case-control study with 53,108 patients with fracture.

Rüdiger J Weiss1, Marius C Wick, Paul W Ackermann, Scott M Montgomery.   

Abstract

OBJECTIVE: To identify the risk of hip and vertebral fractures in patients with rheumatic disorders (RD) and inflammatory bowel diseases (IBD).
METHODS: This population-based case-control study assessed the fracture risk of patients with rheumatoid arthritis, juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), systemic lupus erythematosus, polymyositis/dermatomyositis (PM/DM), systemic sclerosis (SSc), Crohn's disease, and ulcerative colitis (UC). The study cohort comprised 53,108 patients with fracture (66% women) and 370,602 age-matched and sex-matched controls. Conditional logistic regression analysis was performed and results were expressed as OR with corresponding 95% CI.
RESULTS: There was a statistically significant increased fracture risk for all RD and for IBD compared with controls. The magnitude of fracture risk was higher for patients with RD (OR 3, 95% CI 2.9-3.2) than for those with IBD (OR 1.6, 1.4-1.8). The OR in RD ranged from 2.6 (1.3-4.9) for SSc to 4 (3.4-4.6) for AS. The largest increased fracture risk for vertebral fractures was seen in AS (OR 7.1, 6-8.4) and for hip fractures in JIA (OR 4.1, 2.4-6.9).
CONCLUSION: Our results highlight the existence of an increased fracture risk from a variety of underlying causes in patients with RD and IBD. In many inflammatory diseases, implementation of fracture prevention strategies may be beneficial.

Entities:  

Mesh:

Year:  2010        PMID: 20889599     DOI: 10.3899/jrheum.100363

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  49 in total

Review 1.  Bone, inflammation, and inflammatory bowel disease.

Authors:  Manasi Agrawal; Shitij Arora; Jianjun Li; Rabin Rahmani; Li Sun; Adam F Steinlauf; Jeffrey I Mechanick; Mone Zaidi
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

2.  Significantly higher estimated 10-year probability of fracture in lupus patients with bone mineral density comparable to that of healthy individuals.

Authors:  Anselm Mak; Jia Qing Lim; Yang Liu; Alicia Ai-cia Cheak; Roger Chun-man Ho
Journal:  Rheumatol Int       Date:  2012-03-24       Impact factor: 2.631

Review 3.  Effects of anti-tumor necrosis factor α agents on bone.

Authors:  Vivian K Kawai; C Michael Stein; Daniel S Perrien; Marie R Griffin
Journal:  Curr Opin Rheumatol       Date:  2012-09       Impact factor: 5.006

Review 4.  Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.

Authors:  X Wang; S Yan; C Liu; Y Xu; L Wan; Y Wang; W Gao; S Meng; Y Liu; R Liu; D Xu
Journal:  Osteoporos Int       Date:  2016-01-11       Impact factor: 4.507

5.  Osteoporotic hip fractures in non-elderly patients: relevance of associated co-morbidities.

Authors:  Sandra G Pasoto; Liz A K Yoshihara; Lucy C Maeda; Marcia M S Bernik; Paulo A Lotufo; Eloisa Bonfa; Rosa M R Pereira
Journal:  Rheumatol Int       Date:  2011-09-27       Impact factor: 2.631

6.  Fracture risk assessment and osteoporosis treatment disparities in 3,970 Japanese patients with rheumatoid arthritis.

Authors:  Takefumi Furuya; Takayuki Hosoi; Seiji Saito; Eisuke Inoue; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka
Journal:  Clin Rheumatol       Date:  2011-04-13       Impact factor: 2.980

Review 7.  Inflammatory diseases and bone fragility.

Authors:  K Briot; P Geusens; I Em Bultink; W F Lems; C Roux
Journal:  Osteoporos Int       Date:  2017-09-15       Impact factor: 4.507

Review 8.  [Sport and rheumatoid arthritis].

Authors:  D Proschek; S Rehart
Journal:  Z Rheumatol       Date:  2014-06       Impact factor: 1.372

9.  The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report.

Authors:  Hitoshi Saito; Hiroyuki Kakihata; Yosuke Nishida; Sawako Yatomi; Shigeru Nihojima; Yumiko Kobayashi; Hidehiro Tabata; Makoto Nomura
Journal:  J Bone Miner Metab       Date:  2016-10-03       Impact factor: 2.626

10.  Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases.

Authors:  Vivian K Kawai; Carlos G Grijalva; Patrick G Arbogast; Jeffrey R Curtis; Daniel H Solomon; Elizabeth Delzell; Lang Chen; Rita Ouellet-Hellstrom; Lisa Herrinton; Liyan Liu; Edward F Mitchell; C Michael Stein; Marie R Griffin
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-07       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.